Journalartikel
Autorenliste: Wagenlehner, Florian; Wullt, Bjorn; Ballarini, Stefania; Zingg, Daniel; Naber, Kurt G.
Jahr der Veröffentlichung: 2018
Seiten: 107-117
Zeitschrift: Expert Review of Pharmacoeconomics & Outcomes Research
Bandnummer: 18
Heftnummer: 1
ISSN: 1473-7167
eISSN: 1744-8379
DOI Link: https://doi.org/10.1080/14737167.2017.1359543
Verlag: Taylor and Francis Group
Background: Uncomplicated lower urinary tract infections (UTIs) occur in approximately 50% of women, and 20-30% experience recurrent UTI. Data on UTIs and quality of life (QoL) in Europe are limited. Methods: This was an anonymous, self-administered web-based survey conducted in 5 countries (Germany, Switzerland, Poland, Russia and Italy), on adult women who had experienced recurrent UTI and were affected by acute UTI currently or within 4 weeks of study entry. Questions covered disease course; management; social and economic burden; education, income, and health insurance status. QoL was evaluated using the SF-12v2. Results: Participants reported a mean of 5.15 UTI symptoms, ranging from 4.85 - 5.38 in Russia and Germany. There was a mean of 2.78 doctor visits per year (1.74 - 3.71 in Russia and Germany; p < 0.0001). 80.3% of participants had been treated with antibiotics, mean prescriptions ranged from 2.17 (Poland) to 3.36 (Germany) per person per year. A mean of 3.09 days sick leave due to UTIs, and 3.45 days of limited activities, were reported. Although 73.8% of participants had tried prophylaxis recurrence was common and associated with mental stress for a high proportion of women. Conclusions: Our results indicate that recurrent UTIs have a significant impact on QoL of women in Europe.
Abstract:
Zitierstile
Harvard-Zitierstil: Wagenlehner, F., Wullt, B., Ballarini, S., Zingg, D. and Naber, K. (2018) Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT), Expert review of pharmacoeconomics & outcomes research, 18(1), pp. 107-117. https://doi.org/10.1080/14737167.2017.1359543
APA-Zitierstil: Wagenlehner, F., Wullt, B., Ballarini, S., Zingg, D., & Naber, K. (2018). Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT). Expert review of pharmacoeconomics & outcomes research. 18(1), 107-117. https://doi.org/10.1080/14737167.2017.1359543
Schlagwörter
ASCORBIC-ACID; Disease burden; DOUBLE-BLIND; ECONOMIC BURDEN; Mental health; OM-89; ORAL IMMUNOTHERAPY; PROPHYLACTIC AGENT; recurrent urinary tract infections; VAGINAL MUCOSAL VACCINE; WOMEN
